posted
Trial to decide ownership of cancer drug By Mike Clary - Staff Writer - Posted June 2 2005
With their industrial solvent company teetering on the brink of insolvency, Harvey Katz and Claudia Iovino were praying for a financial miracle when along came something that sounded even better: a would-be miracle drug.
T-19 Holistic Nasal Spray promised not only to save International Foam Solutions of Delray Beach from bankruptcy, but cure cancer and make everyone rich as well.
"I told Harvey to go for it," said Iovino, 67, who had recently survived a life-or-death bout with lymphoma.
"Anything to fight cancer sounded like a good thing to me."
And so in the spring of 2003 began a convoluted tale of money and medicine that may be sorted out in U.S. District Court in Fort Lauderdale this week in a battle over licensing rights to a product that some believe could be worth billions of dollars to drug manufacturers. A jury trial was scheduled to start today before U.S. District Judge Daniel T.K. Hurley.
"This is a classic case of deception ...," said Miami attorney John Arrastia, representing the plaintiff in the federal lawsuit. "Researchers want to work with this [drug]. They say, `God, I could get like a Nobel Prize.' But greed is keeping it off the market."
The drug at issue is called Tubercin, a patented compound derived from live tuberculosis cells that is said to stimulate the body's immune system.
The drug has not been approved by the Food & Drug Administration and is not available for sale.
But for several years the inventor of Tubercin, physician Dr. Tai Ho Chung, has prescribed it for his patients in South Korea, including some who credit the drug for halting the spread of their cancers.
Until the spring of 2003, Katz and Iovino had never heard of Tubercin. In a warehouse district south of Linton Boulevard, they made products such as Dumpster Fresh, a deodorant for trash bins, and StyroSolve, which reduces polystyrene to tiny beads.
Then a broker introduced Katz and Iovino to Ronald Shinn, a former chief of research for the California prison system, and Gerry Knight, a onetime administrator with the Oklahoma Insurance Department. Having acquired the rights to Tubercin outside of South Korea, Shinn and Knight were looking for an existing publicly traded company through which to raise capital quickly.
And International Foam Solutions was struggling to stay afloat. "We didn't know anything about the drug business," admitted Iovino. "We needed more money, and this was a way for us to continue."
International Foam Solutions became Hard To Treat Diseases Inc., and Shinn and Knight became its top officers. Katz and Iovino were issued stock, saw about $700,000 in debt paid off, and continued to manufacture StyroSolve.
But in November 2003, Shinn and Knight asked that the merger with International Foam Solutions be rescinded, and announced that the rights to Tubercin were held by ArTec Inc., a Reno-based company in which they had interest.
Katz and Iovino responded by bringing in Plantation accountant Colm King to take over Hard To Treat Diseases.
King then filed suit against Shinn and Knight, alleging the pair misused corporate funds and interfered with company business. King, on behalf of some 5,000 shareholders, is asking for $33 million in damages, and a declaratory judgment granting him the rights to Tubercin.
"We haven't made a penny off of Tubercin," King said. "But the drug is for real."
Dr. Leland Shapiro is one of the few researchers outside South Korea to have worked with Tubercin. An infectious disease specialist at the Denver Veterans Affairs Medical Center, Shapiro was hired by King to conduct tests last year.
The drug "does have promise," Shapiro said.
King said four major pharmaceutical companies have expressed interest in Tubercin. "But they won't deal with me pending litigation," he said.
posted
Judge Daniel T. K. Hurley United States Courthouse 701 Clematis Street West Palm Beach, Florida 33401-5196 (561) 803-3450
JUNE TRIAL CALENDAR
(Updated on Saturday, June 4th, 2005, at 10:25 a.m.)
NOW IN TRIAL: Hard to Treat Diseases, Inc. v. Shinn, 04-80010. The plaintiff is presenting its case-in-chief in this nonjury trial which is being conducted in in courtroom 205C of the U.S. Courthouse in Fort Lauderdale. Counsel estimate the trial will conclude on Wednesday or Thursday of next week.
posted
Hard To Treat Diseases (Pink: HTDS): is involved in bringing the Korean medical technology "Tubercin" to the USA as a new or additive weapon in the cocktail required to fight cancerand other diseases.
Go to http://www.pinksheets.com put HTDS in the window and then save the results to your favorites file - you're going to be needing it.
If somebody hands you a 100-bagger at 0.01 are you going to scratch your tush, wet your pants, call Hillary for Insider Commodities Trading advice - or buy some and get bloody rich...!?!
Anybody who fails to buy HTDS by Wednesday is either a deadhead or a total dumbarse....!!!
posted
I sure hope all those witless idiots who put their hard earned money into QBID (..aka: QFLUB, QFLUSH, and/or Feahwuss Fwankie Fartsnorter's 'Flakey Fairyland Follies'..) have the good sense to buy HTDS...!!!
They are all going to need the HTDS cure from the poverty resulting from their dumbarse choice in stocks, ...or, they'll be needing the associated cure from HTDS for their roaring, acute case AIDS....
If all those witless idiots who put their hard earned money into QBID (..aka: QFLUB, QFLUSH, and/or Feahwuss Fwankie Fartsnorter's 'Flakey Fairyland Follies'..) have the good sense to buy HTDS it may pull them back out of the poor house - or save their lives...!!!
HTDS 0.012 +0.002 (+20.00%) 0 0 8,194,925 or QBID 0.002 +/-0 (+/-0.00% - only bowel movements) 0 0 282,150,227
A new treatment for AIDS that will take the financial monkey off all of the straight people's backs - casued by the foolish, self-indulgent, immoral, irresponsible behavior of the wacked-out homosexual weirdos.....
"....Tubercin for everybody - so it's safe to go into a public toilet again.."!!!
posted
Hard To Treat Diseases (Pink: HTDS): is involved in bringing the Korean medical technology "Tubercin" to the USA as a new or additive weapon in the cocktail required to fight cancerand other diseases. Website:http://www.htdsotc.com/ .
Posts: 118 | Registered: May 2005
| IP: Logged |
posted
It sure would be a good idea for the poor dumb suckers who got "..sucked.." in and stuck in QBID to hedge there bets (..and their life insurance..) with a collection of HTDS shares.
posted
agent 86 sounds like you hav4e done a lot of dd.it is very obvious every thing hangs on the suit do you know how it looks for htds
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
TUBERCIN is an amazing example of development in science and technology at the dawn of the 21st century.
TUBERCIN is a remarkable Immunostimulant that is derived from Mycobacterium Tuberculosis. It is purified and it becomes a safe, non-toxic and non-addictive Immunostimulant.
As an Immunostimulant, TUBERCIN increases the strength in the immune system enabling it to ultimately destroy the cancer cells. Tubercin is effective in strengthening the immune system to eradicate various types of cancer in patients without any side effects. Currently, stages three and four (terminal cancer) are very difficult to combat.
TUBERCIN DOES WORK ON STAGES INCLUDING THREE AND FOUR. Over two thousand patients have been treated with TUBERCIN under strict clinical settings in South Korea at the oldest and very prestigious university hospital in Taegu , Korea , Kyungpook National University Medical School . Today approximately 40 % of these 2000 terminal Cancer patients positively impacted and a significant number has remained cancer free within this 20 year duration. Dr. Tai-Ho Chung the inventor of Tubercin T-5 has published his findings over the last seventeen years in Korean Medical Journals. Dr. Tai-Ho Chung was the former Medical School dean and is currently the Director of the World Health Organization (WHO) Medical Research Center dealing with Hepatitis situated at the Kyungpook National University , Taegu , Korea .
On January 2002, the International Journal of Dermatology, Volume 41. Issue 1., announced the successful treatment of a 77 year old Taegu woman with Acral Lentiginous Melanoma using Tubercin. This woman was diagnosed with terminal Acral Lentiginous Melanoma and her arm was recommended to be amputated to extend her life. She was diagnosed with three—four months to live. She refused amputation and sought Dr. Tai Ho Chung (Inventor) to administer Tubercin. On Dec. 24, 1999 she began treatment with Tubercin and 10 months later the Melanoma cancer disappeared. On December 28, 2000 , an official biopsy was performed and she was declared CANCER FREE .
Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea . The decisive measure to cope with cancer is surgery.
When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells.
Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from micro bacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. ArTec is able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America . In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer . There have been no indications of any adverse side effects in human trials. There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived. Statistically speaking forty percent (40%) is a realistic survival rate among patients experiencing the varying forms of cancer who have been treated with TUBERCIN. Research and Development is complete. Currently Tubercin is in use through compassionate care.
WHAT OTHERS SAY:
ArTec Inc., cites a study that supports essentially how TUBERCIN works in the battle against cancer. Please consult Reuters Health eLine Headlines for. April 25, 2001 which states as follows:
The Immune System can help block, fight cancer - study LONDON (Reuters) - In a finding that could lead to the development of new ways to fight cancer, scientists in the United States " said Wednesday they had firm evidence that the immune system can help prevent tumors. The body's natural defense mechanism helps to fight Infections and other ailments and scientists had suspected it also played a role in defeating cancer cells. Robert Schreiber, of the Washington University School of Medicine in St Louis, and Lloyd Old, of the Ludwig Institute of Cancer Research at memorial Sloan Kettering Cancer Center in New York have now shown that white blood cells called lymphocytes and an immune cell protein known as gamma interferon (IFNg) seek out and destroy cancerous cells. 'This is very exciting because it indicates that immunotherapy has a significant potential use even for the treatment of tumors that are altered by the immunoediting process," said Schreiber.
Also. a press release dated May 14, 2001 from a San Francisco meeting of cancer researchers announced accomplishments have been made, cancer vaccines demonstrate promise of getting the body's immune system to kill tumors the same way it fights off infections. We at ArTec would like to point out that TUBERCIN has no side affects and has been very successful in training T-Cells to attack and kill diseased cells.
NASAL SPRAY:
Utilizing an effective and efficient delivery system for Tubercin is necessary in order to place the product into over the counter market place. The present delivery system is by injections. Needles have a negative impact on consumers, especially if the consumer is not familiar with how to inject oneself property. To attract customers we must have an attractive delivery system that is easy to use and reflects a positive image. ArTec Incorporated has determined that a “Nasal Sprays” is an excellent method for administering Tubercin.
The following statement is from an Article printed in Lycos Health WebMD Search dated July 17, 2001 . By William H. Fray II, PhD, 'The nose contains nerve endings connected directly to two very powerful networks: the olfactory nerves, which control the sense of smell, and the trigeminal nerve, which sends sensations from the face and head to the brain. These nerves provide a: direct shot from the nose to the brain, without stopping in the bloodstream. That means that an immune stimulant can reach the brain in less than 15 minutes, less than half the time it would take if the immune stimulant were injected into a vein. This is important, because immune stimulants that enter the bloodstream are often stopped short before making into the brain by a natural protection mechanism called the blood-brain barrier.
ArTec Inc. has developed a nasal spray which contains Tubercin. The nasal spray will be marketed and utilized as an over the counter product with the intent of providing the following benefits:
1. Pain Management. 2. Enhancement of the Immune System. 3. Prevention. 4. Good Health Management 5. Building of T-cells.
The nasal pump sprayer will provide a precise measured dose delivering a soothing spray of fine mist of the Tubercin. The nasal spray will be safe, natural and an attractive method of distribution of Tubercin without injections.
A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient.
There is recognition that morphine is a trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. Certainly Tubercin should be considered for patients who have strong arthritic pains; when administered to an arthritic patient with such pain the pain has eroded.
posted
Dr. Tai Ho Chung, Ph. D. M.D. Partner, Scientific Advisor and Inventor of Tubercin
Career Objective:
To bring to the world the successful implementation of Tubercin to effectively combat Cancer. As a partner in ArTec, Inc., his role is to insure the scientific aspects of accomplishing our ArTec, Inc.'s missions are met. Specifically, Dr. Chung will play a key role in the successful application and approvals for both United States Food and Drug Administration (FDA) and Korean FDA. Dr. Chung is an integral part of ArTec, Inc., in fulfilling its scientific medical goals and objectives.
Professional Experiences:
Dr. Chung is currently the Director of the World Health Organization Collaborating Centre for Immunological Research and the Prevention and Control of Viral Hepatitis and its Related Disease, in Taegu, Korea. The centre is located at the Kyungpook National University (KNU) School of Medicine, in Taegu, South Korea. He has been the director for the past five years. In addition, he has been the former Dean of the School of Medicine, KNU, Taegu Korea. He is the inventor of Tubercin and also Hepaguard (recently approved by Korean FDA) which is a medical remedy to combat Hepatitis A, B, C, D, and E. Dr. Chung is a distinguished scientist and well versed in medical research of viral diseases such as Cancer and Hepatitis.
Education and Achievements:
Dr. Chung received his Doctor of Medicine from Kyungpook National University in Taegu, Korea in 1958. He received his M.S. degree in 1962 and received his Ph. D. in 1968 from Kyungpook National University in Taegu, Korea. He is a member of the Board of Trustees of the Korean Cancer Society, Korean Immunology Society and a member of the prestigious New York Science Academy. Dr. Chung has been a visiting professor in the United States, Denmark, Brussels, etc. He has authored more than 121 publications. ,
Posts: 118 | Registered: May 2005
| IP: Logged |
posted
Colm King, CEO of HTDS will win this case this week.......
Judge Daniel T. K. Hurley United States Courthouse 701 Clematis Street West Palm Beach, Florida 33401-5196 (561) 803-3450
JUNE TRIAL CALENDAR
(Updated on Saturday, June 4th, 2005, at 10:25 a.m.)
NOW IN TRIAL: Hard to Treat Diseases, Inc. v. Shinn, 04-80010. The plaintiff is presenting its case-in-chief in this nonjury trial which is being conducted in in courtroom 205C of the U.S. Courthouse in Fort Lauderdale. Counsel estimate the trial will conclude on Wednesday or Thursday of next week.
posted
Agent this board has enough to read on it, as it is. PLEASE PLEASE PLEASE!!!!!! Stop posting the same stuff in every sigle catagory. If a stock is as good as you think it is, why in the world would you keep posting it everywhere. If I can see thru your motives, Im sure everyone else can as well If anyone is intrested, you have posted enough links, for anyone to do their own DD. Now ENOUGH!!!! Please take a time out and go to bed.
-------------------- Never underestimate the power of stupid people in large groups. Posts: 222 | From: Southaven, Ms. | Registered: May 2005
| IP: Logged |
posted
This Stock REMINDS ME of a movie CALLED " BOILER ROOM"
PUMP PUMP PUMPITY PUMPITY DDDDDUUUUMMMMPPPP !!!!
-------------------- "When you have got an elephant by the hind legs and he is trying to run away, it's best to let him run." ...... Abe Lincoln ...... 1.5 million Strong :) Posts: 983 | From: Bethel Island, Ca. 94511 | Registered: Feb 2004
| IP: Logged |
quote:If all those witless idiots who put their hard earned money into QBID
Word of advice... If you expect us to take you seriously, don't insult us.
-------------------- As a forum poster, it is ironic that you are held to a higher standard than a Pink Sheet CEO. Posts: 676 | Registered: Apr 2005
| IP: Logged |
posted
My how fast that fell. My apologies for those of you dumb enough to buy this pumper's shares.
-------------------- As a forum poster, it is ironic that you are held to a higher standard than a Pink Sheet CEO. Posts: 676 | Registered: Apr 2005
| IP: Logged |
quote:Originally posted by g-invest: My how fast that fell. My apologies for those of you dumb enough to buy this pumper's shares.
This hasn't fell yet, I bought in this morning just in case agent is telling the truth. Cause if he is I'd hate to miss out. So to me its worth the risk.
Posts: 424 | Registered: Apr 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
